Simvastatin ve Amlodipin'in Hematolojik Parametreler ve Aorta Üzerine Etkilerinin Araştırılması
Bu çalışmada, modern toplumlarda sık olarak karşılaşılan hastalıklardan olan hiperlipidemi ve hipertansiyon durumlarında tercih edilen Simvastatinin ve Amlodipinin hematolojik parametreler ve Aort üzerine etkileri araştırıldı. Ratlara altı ay süreyle bu ilaçların verilmesiyle ortaya çıkan toksik etkiler hematolojik açıdan ve primer hedef organ olan aortanın histopatolojik analizleri ile belirlenmeye çalışıldı. Toplam 48 hayvan her gruptan 12 hayvan olacak şekilde dört deneme grubuna ayrılarak altı ay süreyle beslendi. Gruplar; Kontrol. Simvastatin lOmg/kg . Amlodipin 10 mg/kg . Simvastatin+Amlodipin Simvastatin 10 mg/kg + Amlodipin 10 mg/kg olarak belirlendi. Kontrol grubuna sadece yem ve su. diğer gruplara yem ve suya ilave olarak belirtilen dozlarda ilaçlar oral yolla verildi. Denemenin başında, üçüncü ayda ve deneme sonunda altıncı ayda her gruptan kan örnekleri alınarak hematolojik analizler RBC Alyuvar . WBC akyuvar . Hb Hemoglobin . Ht hematokrit , MCHC Ortalama eritrosit hemoglobin konsantrasyonu . Tromb. Trombosit . MCV Ortalama eritrosit hacmi . MCH Ortalama hemoglobin konsantrasyonu ve LY lenfosit gerçekleştirildi. Deneme sonunda her gruptan 8 hayvana otopsi uygulanarak aort makroskobik ve histopatolojik olarak incelendi. Hematolojik analizlerde üçüncü ve altıncı ayda yapılan ölçümler arasında paralel değerler elde edildi. Kontrolle karşılaşıldığında ilaç uygulanan tüm gruplarda Simvastatin. Amlodipin, Simvastatin + Amlodipin RBC. WBC. Hb. Ht. MCHC. Tromb. düzeylerinde artış görülürken. MCV. MCH ve LY düzeylerinde ise anlamlı düşüş gözlendi. Aorta örneklerinin makroskobik ve mikroskobik incelenmesi sonucunda ilaç uygulanan tüm gruplarla kontrol grubu arasında her hangi bir farklılık bulunmadı. Sonuç olarak, simvastatin ve amlodipinin yalnız ve kombine olarak ratlara altı ay süreyle verilmesi anlamlı hematolojik değişiklikler yapabilmesi ve bu ilaçların uzun süreli kullanım gerektirmeleri nedeniyle, klinik çalışmalarla da desteklenmesi gerekmektedir
Investigation of Effects on the Henıatological Parameters and Aorta of Simvastatin and Amlodipin
In this study hematological effects of Simvastatin and Amlodipin commonly used in developed societies were investigated. Side effects were determined hematological. macroscopic and histopathological analyses by giving these drugs to rats for six months single and in combination. A total of 48 rats were divided into 4 teratment groups each containing 12 and fed for six months. Groups are Control, Simvastatin 10 mg/kg, Amlodipin 10 mg/kg and Simvastatin 10 mg/kg+Amlodipin 10 mg/kg. Control group was fed only feed and water. Other groups were treated with drugs by orally with doses above and fed with basal diet and water. Blood samples total blood celi were taken from animals on third and sixth months of the treatment and blood hematological analyses were performed. Paraleli results were obtained in hematological analyses Hb Hemoglobin . Ht Hematocrit . MCHC Mean corpuscular hemoglobin consantration , RBC Red blood celi , WBC White blood celi . MCV Mean corpuscular volüme . MCH Mean corpuscular hemoglobin . Thromb Trombocyt and LY Lymphocvt between 3rd and 6,h months of the experiment compared to control. Hb. Ht. and MCHC values were observed higher than control. while RBC, WBC. MCV. MCH. Thromb and LY values were decreased in drugs treated groups Simvastatin. Amlodipin. Simvastatin plus Amlodipin . As a result. the uses of simvastatin and amlodipin single and in combination caused signifıcant hematological changes and degeneration in hemapoetik organs in rats given drugs for six months. At the end of the treatment eight animals were killed for makroskobik and histopathological analyses and aorta samples were analysed microscobically. However, especially. simvastatin can cause antiinflamatuar effects and prevent intimal thickening in aorta samples. but in our study there is no microscobic and histopathologic fındings. As a result. the uses of simvastatin and amlodipin single and in combination caused signifıcant hematological changes in rats given drugs for six months and hematological analyses should be repeated at spesific intervals.
___
- 1. Ziversmit DB (1979) Atherogenesis: a
postprandalphenemon,Cic\A
- 2. Marz W. Wollschlager II. Klein G, Nei BA
and
Wehling M (1999) Koroner kalp hastalığı
bulunan bir hastapopulasyonıında
siınvastatin ile karşılaştırmalı olarak
atorvastatin ile sağlanan düşük dansiteli
lipoprotein kolesterol düşürücü tedavinin
güvenirliği (TARGET TANGİBLE
Çalışması). The American Journal of
Cardiology. 1999. Julv 1.84.1 -8
- 3. Isusi E. Aspichueta P. Liza M. Hernandez
LM.
Diaz C. Hernandez G and et ali (2000)
Short and long ter m effects ofatorvastatin.
lovaslatin and simvastatin on the cellular
melabolisnı of cholesteryl eslers and
VLDL secretion in hepotocytes,
Atherosclerosis, 2000. 153. 283- 294.
- 4. Karaca I. Akbulut M, İlkay E. Üstündağ B,
Özbay Y ve Arslan N (1999)
Hiperlipidemik hastalarda simvastatinin
etkinliği ve güvenirliği. T Klin Kardiyoloji
1999. 12. 100- 103.
- 5. Kayaalp O (2000a) Antihipertansif İlaçlar
In “Rasyonel Tedavi Yönünden Tıbbi
Farmakoloji ” Ed. by Hacettepe TAŞ
Kitapçılık Ltd Şti, 1. cilt. 8. baskı 423-471
- 6. Çalışkan S, Çalışkan M. Kuralay F and
Onvural
B (2000) Effects of simvastatin therapy on
blood and tissııe ATP /eveIs and
erythrocyte membrane lipid composition.
Res Exp Med(Berl), 2000. Feb, 199 (4),
189-194.
- 7. Sharifı AM and Schiffrin EL (1998)
Apoptosis in
vaskulatııre of spontaneoıısly hypertansive
rats effect of an angiotensin converting
emzyme inhihitor and a calcium channel
antagorıist, American Journal of
Hypertansion. 11. 1108- 1116.
- 8. Sparrow CP. Burton CA. Flernandez M.
Mundt S,
Hassing H, Patel S and et ali (2001)
Simvastatin has anti-inflamatory and
antiatherosclerotic activities independent
of plasma cholesterol lowering.
Arterioscler Thromb Vasc Biol. 21, 115-
121.
- 9. Mital S, Magneson A, Lake KE, Liao J.
Forfıa PR
and Ilintze TH (2000) Simvastatin actssynergistically with ACE inhibitors or
amlodipine to decrease oxvgen consumption
in rat hearts. J Cardiovasc Phannacol. 2000.
Aug. 36 (2). 248-254.
- 10. Suzuki M. Yamanaka K. Nabata H and
Tachibana M (1993) Long terin effects of
aınlodipine on organ damage. stroke and life
span in stroke prone spontaneously
hypertensive rat s. Eur J Phannacol. Aprl. 228
(5-6). 269-274.
- 1!. Khemissa-Akouz F, Ouguergouz F. Şulem P.
Tkoub el M and Vaucher E (2002) Amlodipine
induced acııte hepatitis. Gastroenterol Clin
Biol. Jun-Jul. 26 (6-7). 637-638.
- 12. KanathurN. Mathai MG. Bvrd RPJr. Fields
CL and Roy TM (.2001) Simvastatin-diltiazem
drııg interaction safely resulting in
rhabdomyolysis and hepatitis. Tenn Med.
2001. Sep. 94 (9). 339-341.
- 13. Mehregan DR. Mehregan DA and Pakideh S
(1998) Chelitis dne to treatment with
simvastatin, Cutis. 1998. Oct. 62 (4). 197-198.
- 14. Lantuejoul S. Brambilla E. Brambilla C and
Devovassoux G (2002) Statin-induced fibrotic
nonspesific interstitial pnemonia, Eur Respır
J. 2002. Mar. 19 (3). 577-580.
- 15. Koşay S. Oktay Ş (1992)
Antihipertansifİlaçlar İn "Farmakoloji İlaç
Uygulamalarında Temel Kavramlar” Ed by
İsmet Dökmeci. Nobel Tıp Kitabevleri. 233-
241. Çapa, İstanbul.
- 16. Kayaaip O (2000b) Hipolipidemik ilaçlar In
"Rasyonel Tedavi Yönünden Tıbbi
Farmakoloji" Ed. by Hacettepe TAŞ
Kitapçılık Ltd Şti. 1. cilt. 8. baskı. 567-587.
Ankara.
- 17-Malaterre HR. Kallee K and Daver LMH
(1999) Hvponatremia and amlodipine therapy,
Cardiovascular Drugs and Therapy. 1999. 13.
171-172.
- 18. Kusus M. Stopleton DD. Lertora JJ. Simon EE
and Dreischbach AW (2000) Rhabdomyolysis
and acııte renal failure in a cardiac transplant
recipient dne to mııltiple drııg interactions.
Am J Med Sci. 2000. Dec. 320 (6). 394-397.
- 19. Mitani H. Bandah T. îshikawa J, Kimura M.
Tatsuka T and Hayashi S (1996) İnhibitory
effects of fluvastatin.a new HMG-CoA
reduktase inhibitor, on the increase in
vascıılar ACE activity in cholesterol-fed
rabbits, Br J Phannacol. 1996.Nov. 119(6).
1269-1275.
- 20. Esper RJ. Machado R. Vilarino J, Cocharron
JL, İngino CA. Guiııazu G and el ali (2000)
Endothelium-dependent responses in patients
yvith hypercholestrolemic coronary artery
disease ıınder the effects of simvastatin and
enalapril. either separatelv or combined. Am
Heart J. 2000. Oct. 140 (4)’. 684-689.
- 21. Teo KK. Burton JR. Buller CE. Plante S.
Catellier D. Tymchak W and et ali (2000)
Longterm effects of cholesterol lowering and
angiotensin-converting enzyme inhibilion on c
o r on ary a thero sc l ero s i s i: The
simvastatin enalapril coronary
atherosclerosis trial(SCAT). Circulalion. Oct.
10. 102 (15). 1748-1754.
- 22. Azie NE. Broter DC. Becker PA. Jones DR
and Hail SD (1998 ) 77te interaction of
diltiazem xvith lovastatin and provastatin,
Clin Phannacol Ther. 1998. Oct. 64(4). 369-
377.
- 23. Marumo H. Satah K. Yamamoto A. Kaneto S
and Ichihara K (2001) Simvastatin and
atorvastatin enlıance hypotensive effect of
diltiazem in rats. Yakugaku Zasshi. 2001. Oct.
121(10). 761-764.
- 24. Marino MR. Vachharojani NN and
Hadjilambris OW (2000) Irbesartan does not
affect the pharmacokinetics of simvastatin in
healthv subjects, J Clin Pharmacol. 2000.
Aug. 40 (8). 875-879.
- 25. Meyer BH. Scholtz HE. Muller FO. Luus HG.
Rey N, Seibert-Grafe M and et ali (1994)
Lack of interaction betsveen ramipril and
simvastatin, Eur J Clin Pharmacol. 1994. 47
(4). 373-375.
- 26. Marche P. Herembert T and Zhu DL (1997)
Pharmocologic treatment of aterosklerozis:
beyond lipid lowering therapy, Int. J. Cardiol,
1997, Dec 31.62(2). 17-22.
- 27. Palinski W (2001) Nexv evidence for
benefıcial effects of statins unrelated to lipid
lowering, ArteriosclerThrombVasc Biol.
2001.21.3-5.
- 28. Canadian Council on Animal Çare. Gıtide to
the çare and tise of experimental animals,
volume 1.86
- 29. NishimuraT. Faul JL, Berry GJ. Vazsar
LT, Qiu D, Pearl RG and et ali (2002)
Simvastatin attermates smooth muscle
neointimal proliferation on pulmoner
hypertension in rat s, American Journal of
Respiratory and Critical Çare Medicine,
2002,166,1403-1408.
- 30. Fetkovska N. Ulicna L and Jakubouska Z
(1993) İnhibition of trombocyte activity in
atherogenesis and thrombogenesis using
isrodipine and ot her calcium
antagonists,Vnitr Lek. 1993. Apr, 39 (4).
326-333.
- 31. Nebe B. Halehausen C. Rychly J and
Urbozsek W (2002) İmpaired mechanisms
of leukocyte adhesion in vitro by the
calciımı channel antagonist mibefradil.
Cardiovaskuler Drugs and Therapy.
2002.16.183-193.
- 32. Pruefer D. Scalia R and Lefer AM (1999)
Simvastatin inhibits leukocyte-endothelial
celi interactions and protects against
inflamatory processes in
normocholesterolemic rats, Arterioscler
Thromb Vasc Biol. Dec. 19 (12), 2894-
2900.
- 33. Kürşat T Veteriner Klinik Laboratuvar
Teşhis, Eritrosit bozuklukları ve testleri. 18
- 34. Chen Z. Fukutomi T. Zago AC. Ehlers R.
Detmers PA. Wright SD and et ali (2002)
Simvastatin reduced neointimal thickening
in low density lipoprotein receptor
deficient mice after experimental
angioplasty without changing plasma
lipids. Circulation. 2002, Jul2,106(1). 20-
23.